PMID- 15892805
OWN - NLM
STAT- MEDLINE
DCOM- 20050711
LR  - 20191210
IS  - 1464-4096 (Print)
IS  - 1464-4096 (Linking)
VI  - 95
IP  - 9
DP  - 2005 Jun
TI  - Quantitative molecular urinary cytology by fluorescence in situ hybridization: a 
      tool for tailoring surveillance of patients with superficial bladder cancer?
PG  - 1219-25
AB  - OBJECTIVE: To determine whether it is possible to stratify patients with 
      superficial bladder cancer into low- and high-risk groups for tumour 
      recurrence/progression based on the chromosomal pattern detected by fluorescence 
      in situ hybridization (FISH) in one urine cytology specimen used for follow-up 
      testing. PATIENTS AND METHODS: Voided urine samples from 47 consecutive patients 
      with urinary tract neoplasms (13 with no history of urothelial malignancy and 34 
      under follow-up after complete transurethral resection of superficial urothelial 
      carcinoma of the bladder) were evaluated by liquid-based cytology (ThinPrep(R), 
      CYTYC Corp., Boxborough, MA, USA) and UroVysion FISH (Vysis-Abbott, Downers 
      Grove, IL). RESULTS: Of the 34 patients under surveillance, the UroVysion test 
      was negative in four, 17 had loss of 9p21 sequences either alone or combined with 
      low-frequency trisomy/ies or tetrasomy/ies of chromosomes 3, 7 and 17 in single 
      cells (low-risk FISH), and 13 also had complex aneusomies of the remaining 
      chromosomes (high-risk FISH). One of the four FISH-negative neoplasms, four of 
      the 17 low-risk FISH cases and five of the 11 informative high-risk FISH-positive 
      patients developed recurrence. Progression occurred only in patients with 
      high-risk FISH results, showing high-frequency complex chromosomal polysomies 
      (four of 11). CONCLUSION: The results from this pilot study indicate that the 
      UroVysion FISH test may help to individually assess the clinical behaviour of 
      superficial bladder cancer, based on the chromosomal pattern of exfoliated tumour 
      cells in follow-up urinary cytology. It might be of use to identify those 
      patients likely to progress at earlier and curable stages of disease, and 
      lengthen the surveillance period in those with persistent or recurrent low-risk 
      disease.
FAU - Bollmann, Magdolna
AU  - Bollmann M
AD  - Institute of Pathology, Bonn-Duisdorf, Bonn, Germany.
FAU - Heller, Hildegard
AU  - Heller H
FAU - Bankfalvi, Agnes
AU  - Bankfalvi A
FAU - Griefingholt, Harald
AU  - Griefingholt H
FAU - Bollmann, Reinhard
AU  - Bollmann R
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - England
TA  - BJU Int
JT  - BJU international
JID - 100886721
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Chromosome Aberrations
MH  - Chromosomes, Human, Pair 3/genetics
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - In Situ Hybridization
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*genetics/pathology
MH  - Pilot Projects
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Urinary Bladder Neoplasms/*genetics/pathology
EDAT- 2005/05/17 09:00
MHDA- 2005/07/12 09:00
CRDT- 2005/05/17 09:00
PHST- 2005/05/17 09:00 [pubmed]
PHST- 2005/07/12 09:00 [medline]
PHST- 2005/05/17 09:00 [entrez]
AID - BJU5509 [pii]
AID - 10.1111/j.1464-410X.2005.05509.x [doi]
PST - ppublish
SO  - BJU Int. 2005 Jun;95(9):1219-25. doi: 10.1111/j.1464-410X.2005.05509.x.